Breaking news today as, for the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair genes. Read more about the new approval.
Historic cancer drug approval has roots at Johns Hopkins and its Bloomberg~Kimmel Institute laboratories and clinics
Share This Post